A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 938 participants.
Also called NCT04657003
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 938 participants
- Sponsor
- Registry
-
NCT04657003
-
- Other papers using this trial's data
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Brazil, India, Japan, Puerto Rico, Russia, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT04657003. Randomized; double masking; primary purpose treatment. Start 2021-03-29 (actual); primary completion 2023-03-16 (actual). Results posted on 2024-04-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
- Acronym
- SURMOUNT-2
- Condition
- Type 2 Diabetes
- Condition
- Overweight
- Condition
- Obesity
- Intervention (Drug)
- Tirzepatide
- Intervention (Other)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct04657003- Content hash
6a05a442120aa743c37d774c2b9408673ea2f225c965364400ef1241d92209de